ClinicalTrials.gg
DrugBiological

CA-4948 clinical trials

Also written CA-4948, Emavusertib and AU 4948.

studies test it
10
open now
6
in phase 3
0
first study started
2017

How each study uses CA-4948 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the CA-4948 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948
5
IRAK4 Inhibitor CA-4948
5

Development codes

CA-4948
9
AU 4948
5

Other names

Emavusertib
9

Studies by the year they started

10 studies that test it; most in 2023 (2)

Studies that test CA-4948, by start year
YearStudies
20171
20201
20221
20232
20241
20252
20262

By phase

A phase 1/2 study counts in both.

Phase 1
7
Phase 2
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 7

National Cancer Institute (NCI) (4) · Curis, Inc. (3) · Washington University School of Medicine (1) · Mayo Clinic (1) · University of Leipzig (1)

Often tested with

Tested in the same studies.

Azacitidine (1) · Busulfan (1) · Cytarabine (1) · Daunorubicin (1) · Decitabine and cedazuridine drug combination (1) · Enasidenib (1) · Epoetin Alfa (1) · Fludarabine (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test CA-4948.

Studies

Open first, then newest update. How each study uses CA-4948 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 10

Given beside what is tested · 1 — CA-4948 is usual care or a partner of the new treatment

Codes

What other systems call CA-4948 · ClinicalTrials.gg INT002036

  • MeSH (NLM) C000729138CA-4948One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.